MX2021009837A - Vacuna de influenza atenuada en vivo composicion y proceso de preparacion de los mismos. - Google Patents

Vacuna de influenza atenuada en vivo composicion y proceso de preparacion de los mismos.

Info

Publication number
MX2021009837A
MX2021009837A MX2021009837A MX2021009837A MX2021009837A MX 2021009837 A MX2021009837 A MX 2021009837A MX 2021009837 A MX2021009837 A MX 2021009837A MX 2021009837 A MX2021009837 A MX 2021009837A MX 2021009837 A MX2021009837 A MX 2021009837A
Authority
MX
Mexico
Prior art keywords
laiv
strains
live attenuated
influenza vaccine
attenuated influenza
Prior art date
Application number
MX2021009837A
Other languages
English (en)
Inventor
Rajeev Mhalasakant Dhere
Leena Ravindra Yeolekar
Milan Shomenath Ganguly
Parikshit Dharampal Tyagi
Umesh Gorakh Sagar
Swapnil Prabhakar Narale
Yashodhan Dilip Anaspure
Sham Ramdas Tupe
Original Assignee
Serum Inst Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Inst Of India Pvt Ltd filed Critical Serum Inst Of India Pvt Ltd
Publication of MX2021009837A publication Critical patent/MX2021009837A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona composiciones y métodos para fabricar y obtener una composición de vacuna viva atenuada contra la influenza (LAIV) que puede administrarse por vía intranasal para proporcionar protección contra la infección por el virus de la influenza. Dichas cepas LAIV se basan en fenotipos adaptados al frío, sensibles a la temperatura y atenuados de virus donantes principales (MDV) que contienen los genes de glucoproteína de superficie de las cepas de influenza pandémica o estacional de tipo salvaje. Además, dichas cepas LAIV se adaptan aún más para crecer en células MDCK (células de riñón canino Madin Darby). Se evita el uso de huevos en la fabricación de vacunas a gran escala. El proceso de purificación carece de etapas de cromatografía. Dicha composición LAIV incluye uno o más virus de vacuna contra la Influenza atenuados vivos y carece de polímeros y tensioactivos.
MX2021009837A 2019-02-15 2020-02-07 Vacuna de influenza atenuada en vivo composicion y proceso de preparacion de los mismos. MX2021009837A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921006071 2019-02-15
PCT/IN2020/050121 WO2020165912A1 (en) 2019-02-15 2020-02-07 Live attenuated influenza vaccine composition and process for preparation thereof

Publications (1)

Publication Number Publication Date
MX2021009837A true MX2021009837A (es) 2021-09-10

Family

ID=69740470

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009837A MX2021009837A (es) 2019-02-15 2020-02-07 Vacuna de influenza atenuada en vivo composicion y proceso de preparacion de los mismos.

Country Status (20)

Country Link
US (1) US20220211837A1 (es)
EP (1) EP3924052A1 (es)
JP (1) JP2022520443A (es)
KR (1) KR20210129073A (es)
CN (1) CN113646047A (es)
AR (1) AR119691A1 (es)
AU (1) AU2020222113A1 (es)
BR (1) BR112021016059A2 (es)
CA (1) CA3130036A1 (es)
CL (1) CL2021002111A1 (es)
CO (1) CO2021010751A2 (es)
IL (1) IL285526A (es)
JO (1) JOP20200037A1 (es)
MA (1) MA54942A (es)
MX (1) MX2021009837A (es)
PE (1) PE20212322A1 (es)
SG (1) SG11202108766RA (es)
TW (1) TW202045205A (es)
UY (1) UY38587A (es)
WO (1) WO2020165912A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0202846A3 (en) * 1999-09-24 2003-12-29 Smithkline Beecham Biolog Intranasal influenza virus vaccine
CA2517181C (en) * 2003-02-25 2013-07-16 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
ES2633471T3 (es) * 2004-10-06 2017-09-21 Medimmune, Llc Composiciones de vacuna contra la gripe estables a temperatura de refrigerador
RU2015103990A (ru) * 2008-09-24 2015-10-27 Медиммун, Ллк Способы культивирования клеток, размножения и очистки вирусов
CA2993242C (en) * 2010-04-15 2020-12-15 Shin Nippon Biomedical Laboratories, Ltd. Methods and compositions for intranasal delivery
TWI670085B (zh) * 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
WO2017047089A1 (en) * 2015-09-16 2017-03-23 Shin Nippon Biomedical Laboratories, Ltd. Vaccine compositions
CA3069444A1 (en) * 2017-07-11 2019-01-17 Universal Stabilization Technologies, Inc. Method for preserving biopharmaceuticals

Also Published As

Publication number Publication date
MA54942A (fr) 2021-12-22
BR112021016059A2 (pt) 2021-10-13
KR20210129073A (ko) 2021-10-27
AR119691A1 (es) 2022-01-05
PE20212322A1 (es) 2021-12-14
SG11202108766RA (en) 2021-09-29
CA3130036A1 (en) 2020-08-20
JOP20200037A1 (ar) 2020-08-15
US20220211837A1 (en) 2022-07-07
CO2021010751A2 (es) 2021-09-09
EP3924052A1 (en) 2021-12-22
CN113646047A (zh) 2021-11-12
CL2021002111A1 (es) 2022-01-28
TW202045205A (zh) 2020-12-16
IL285526A (en) 2021-09-30
AU2020222113A1 (en) 2021-10-07
UY38587A (es) 2020-09-30
JP2022520443A (ja) 2022-03-30
WO2020165912A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
Thomas et al. Cell-mediated protection in influenza infection
Wong et al. Traditional and new influenza vaccines
Easterbrook et al. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice
Tian et al. Protective efficacy in chickens, geese and ducks of an H5N1-inactivated vaccine developed by reverse genetics
Quan et al. Progress in developing virus-like particle influenza vaccines
Becker et al. Influenza vaccines: successes and continuing challenges
KR100927517B1 (ko) 생균 백신
Quiñones-Parra et al. Universal immunity to influenza must outwit immune evasion
Johansson et al. Changing perspective on immunization against influenza
Lee et al. Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M 2 vaccination
HRP20120790T1 (hr) Cjepiva protiv influence sa niskom koliäśinom aditiva
Noh et al. Influenza vaccines: unmet needs and recent developments
Isakova-Sivak et al. Safety, immunogenicity and infectivity of new live attenuated influenza vaccines
JP2012511914A5 (es)
CN102304495A (zh) 高效表达ha蛋白的重组流感病毒及其制备方法和应用
Jang et al. Cross-protective immune responses elicited by live attenuated influenza vaccines
CN102220293B (zh) 犬流感重组病毒及其制备方法和应用
Wohlbold et al. An H10N8 influenza virus vaccine strain and mouse challenge model based on the human isolate A/Jiangxi-Donghu/346/13
Lee et al. Genetic evolution of H5 highly pathogenic avian influenza virus in domestic poultry in Vietnam between 2011 and 2013
RU2014140731A (ru) Варианты гемагглютинина и нейраминидазы гриппа
Zhou et al. High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1
TW200920842A (en) Vero cell-based influenza virus strains and vaccines
Muramoto et al. Molecular characterization of the hemagglutinin and neuraminidase genes of H5N1 influenza A viruses isolated from poultry in Vietnam from 2004 to 2005
JOP20200037A1 (ar) تركيبة لقاح إنفلونزا موهن حي وعملية تحضيره
US20220160863A1 (en) High growth influenza virus